Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 431 Carcinoma, Non-Small-Cell Lung 391 Prostatic Neoplasms 267 Lung Neoplasms 157 Stomach Neoplasms 125 Neoplasms 101 Squamous Cell Carcinoma of Head and Neck 98 Neoplasm Metastasis 84 Head and Neck Neoplasms 82 Esophageal Neoplasms 66 Ovarian Neoplasms 52 Urinary Bladder Neoplasms 39 Pancreatic Neoplasms 37 Nasopharyngeal Carcinoma 36 Sarcoma 35 Triple Negative Breast Neoplasms 28 Carcinoma, Squamous Cell 28 Carcinoma, Ovarian Epithelial 25 Adenocarcinoma of Lung 25 Adenocarcinoma 25 Esophageal Squamous Cell Carcinoma 23 Adenocarcinoma Of Esophagus 23 Carcinoma, Transitional Cell 22 Recurrence 20 Fallopian Tube Neoplasms 19 Breast Neoplasms, Male 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 18 Melanoma 17 Carcinoma 17 Unspecified Adult Solid Tumor, Protocol Specific 16

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡